Renal transplantation from hepatitis B surface antigen (HBsAg)-positive donors to HBsAg-negative recipients: A case of post-transplant fulminant hepatitis associated with an extensively mutated hepatitis B virus strain and review of the current literature

Transplant Infectious Disease

Volumn 15, Issue 4, 2013, Pages 393-399

  Magiorkinis, E ^a   Paraskevis, D ^a   Pavlopoulou, I D ^b   Kantzanou, M ^a   Haida, C ^a   Hatzakis, A ^a   Boletis, I N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Escape mutant; Fulminant; HBV; HBV vaccination; Hepatitis; Renal transplant

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT HEPATITIS B VACCINE; TACROLIMUS;

ARTICLE; FRAMESHIFT MUTATION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS GENOME; VIRUS TRANSMISSION;

EID: 84880783571     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12094     Document Type: Article

References (52)

1. Baumert TF, Thimme R, von Weizsacker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13 (1): 82-90.
2. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991; 324 (24): 1705-1709.
3. Kosaka Y, Takase K, Kojima M, et al. Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 1991; 100 (4): 1087-1094.
4. Simini B. Italian outbreak of fulminant hepatitis B reported. Lancet 1998; 351 (9103): 653.
5. Petrosillo N, Ippolito G, Solforosi L, Varaldo PE, Clementi M, Manzin A. Molecular epidemiology of an outbreak of fulminant hepatitis B. J Clin Microbiol 2000; 38 (8): 2975-2981.
6. Bracho MA, Gosalbes MJ, Gonzalez F, Moya A, Gonzalez-Candelas F. Molecular epidemiology and evolution in an outbreak of fulminant hepatitis B virus. J Clin Microbiol 2006; 44 (4): 1288-1294.
7. Igaki N, Nakaji M, Moriguchi R, et al. An outbreak of fulminant hepatitis B in immunocompromised hemodialysis patients. J Gastroenterol 2003; 38 (10): 968-976.
8. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2 (8663): 588-591.
9. Okamoto H, Yotsumoto S, Akahane Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64 (3): 1298-1303.
10. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991; 324 (24): 1699-1704.
11. Chen Y, Michitaka K, Matsubara H, Yamamoto K, Horiike N, Onji M. Complete genome sequence of hepatitis B virus (HBV) from a patient with fulminant hepatitis without precore and core promoter mutations: comparison with HBV from a patient with acute hepatitis infected from the same infectious source. J Hepatol 2003; 38 (1): 84-90.
12. Ozasa A, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44 (2): 326-334.
13. Inoue K, Ogawa O, Yamada M, Watanabe T, Okamoto H, Yoshiba M. Possible association of vigorous hepatitis B virus replication with the development of fulminant hepatitis. J Gastroenterol 2006; 41 (4): 383-387.
14. Nagasaki F, Ueno Y, Niitsuma H, et al. Analysis of the entire nucleotide sequence of hepatitis B causing consecutive cases of fatal fulminant hepatitis in Miyagi Prefecture Japan. J Med Virol 2008; 80 (6): 967-973.
15. Swofford DL; PAUP*: Phylogenetic Analysis Using Parsimony (*and Other Methods). Version 4.0 beta. Sunderland, Massachusetts: Sinauer Associates, 2002.
16. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011; 28 (10): 2731-2739.
17. Aritomi T, Yatsuhashi H, Fujino T, et al. Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan. J Gastroenterol Hepatol 1998; 13 (11): 1125-1132.
18. Sato S, Suzuki K, Akahane Y, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122 (4): 241-248.
19. Hayashi K, Katano Y, Takeda Y, et al. Association of hepatitis B virus subgenotypes and basal core promoter/precore region variants with the clinical features of patients with acute hepatitis. J Gastroenterol 2008; 43 (7): 558-564.
20. Hayashi K, Katano Y, Chuong TX, et al. Prevalence of hepatitis B virus subgenotypes and basal core promoter, precore variants in patients with acute hepatitis B in central Vietnam. Intervirology 2009; 52 (1): 22-28.
21. Friedt M, Gerner P, Wintermeyer P, Wirth S. Complete hepatitis B virus genome analysis in HBsAg positive mothers and their infants with fulminant hepatitis B. BMC Gastroenterol 2004; 4: 11.
22. Szmaragd C, Foster GR, Manica A, Bartholomeusz A, Nichols RA, Balloux F. Genome-wide characterisation of hepatitis B mutations involved in clinical outcome. Heredity 2006; 97 (6): 389-397.
23. Pult I, Chouard T, Wieland S, Klemenz R, Yaniv M, Blum HE. A hepatitis B virus mutant with a new hepatocyte nuclear factor 1 binding site emerging in transplant-transmitted fulminant hepatitis B. Hepatology 1997; 25 (6): 1507-1515.
24. Sumethkul V, Ingsathit A, Jirasiritham S. Ten-year follow-up of kidney transplantation from hepatitis B surface antigen-positive donors. Transplant Proc 2009; 41 (1): 213-215.
25. Mohrbach J, Janssen MW, Heine GH, et al. Successful outcome of kidney transplantation from a HBV-DNA positive donor into recipients with cleared HBV-infection using a pre-emptive therapy approach. J Clin Virol 2010; 49 (1): 53-57.
26. Wu W, Chen Y, Ruan B, Li LJ. Gene heterogeneity of hepatitis B virus isolates from patients with severe hepatitis B. Hepatobiliary Pancreat Dis Int 2005; 4 (4): 530-534.
27. Stange MA, Tutarel O, Pischke S, et al. Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. Z Gastroenterol 2010; 48 (2): 258-263.
28. Matsue K, Aoki T, Odawara J, et al. High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients. Eur J Haematol 2009; 83 (4): 357-364.
29. von Wagner M, Zeuzem S. [Prevention and therapy of reactivation of hepatitis B in immunosuppressed patients]. Dtsch Med Wochenschr 2009; 134 (6): 255-258.
30. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol 1994; 68 (3): 1651-1659.
31. Berber I, Aydin C, Yigit B, Turkmen F, Titiz IM, Altaca G. The effect of HBsAg-positivity of kidney donors on long-term patient and graft outcome. Transplant Proc 2005; 37 (10): 4173-4175.
32. Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15 (20): 2489-2499.
33. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52 (2): 272-279.
34. Vizzini G, Gruttadauria S, Volpes R, et al. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts. Clin Transplant 2011; 25 (1): E77-E81.
35. Park KS, Han DJ, Park JB, Park JS, Park S. Long-term outcome of hepatitis B-positive renal alograft recipients after development of antiviral treatment. Clin Nephrol 2012; 78: 391-398.
36. Pilmore HL, Gane EJ. Hepatitis B-positive donors in renal transplantaion increasing the deceased donor pool. Transplantation 2012; 94: 205-210.
37. Kim KH, Ahn SH, Chung HY, et al. Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J Gastroenterol Hepatol 2004; 19 (8): 847-853.
38. Sterneck M, Gunther S, Gerlach J, et al. Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis. J Hepatol 1997; 26 (4): 754-764.
39. Sterneck M, Gunther S, Santantonio T, et al. Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation. Hepatology 1996; 24 (2): 300-306.
40. Sterneck M, Kalinina T, Gunther S, et al. Functional analysis of HBV genomes from patients with fulminant hepatitis. Hepatology 1998; 28 (5): 1390-1397.
41. Sobhonslidsuk A, Sornmayura P, Sumethkul V. Failure of hepatitis B surface antibody to protect acute fulminating hepatitis in a renal transplant recipient. J Med Assoc Thai 2006; 89 (Suppl 2): S257-S261.
42. Kojima H, Abei M, Takei N, et al. Fatal reactivation of hepatitis B virus following cytotoxic chemotherapy for acute myelogenous leukemia: fibrosing cholestatic hepatitis. Eur J Haematol 2002; 69 (2): 101-104.
43. Tanaka S, Yoshiba M, Iino S, et al. A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant. Kidney Int 1995; 48 (6): 1972-1978.
44. Kitano K, Kobayashi H, Hanamura M, et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol 2006; 77 (3): 255-258.
45. Aye TT, Uchida T, Becker SO, et al. Variations of hepatitis B virus precore/core gene sequence in acute and fulminant hepatitis B. Dig Dis Sci 1994; 39 (6): 1281-1287.
46. Sayiner AA, Agca H, Sengonul A, Celik A, Akarsu M. A new hepatitis B virus vaccine escape mutation in a renal transplant recipient. J Clin Virol 2007; 38 (2): 157-160.
47. Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002; 299 (1): 88-99.
48. Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 2009; 15 (46): 5761-5769.
49. Kalinina T, Riu A, Fischer L, Will H, Sterneck M. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. Hepatology 2001; 34 (2): 385-394.
50. Kramvis A, Kew MC, Bukofzer S. Hepatitis B virus precore mutants in serum and liver of Southern African blacks with hepatocellular carcinoma. J Hepatol 1998; 28 (1): 132-141.
51. Sainokami S, Abe K, Sato A, et al. Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection. J Gastroenterol 2007; 42 (3): 241-249.
52. Bagaglio S, Albarello L, Biswas P, Uberti-Foppa C, Fortis C, Morsica G. Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report. J Med Case Reports 2009; 3: 110.